2. Search Result
Search Result
Pathways Recommended: JAK/STAT Signaling
Results for "

Vitiligo jak Inhibitors

" in MedChemExpress (MCE) Product Catalog:

610

Inhibitors & Agonists

7

Screening Libraries

4

Fluorescent Dyes

8

Biochemical Assay Reagents

7

Peptides

3

Inhibitory Antibodies

75

Natural
Products

16

Recombinant Proteins

31

Isotope-Labeled Compounds

23

Antibodies

5

Click Chemistry

13

Oligonucleotides

3

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-30272
    Monobenzone
    1 Publications Verification

    		 Hapten Cancer
    Monobenzone is a potent skin depigmenting agent. Monobenzone induces depigmentation and exhibits good potential for vitiligo research. Monobenzone is a potent inhibitor of RNR (Ribonucleotide reductase) enzyme activity by targeting RRM2 (a regulatory small subunit M2 of RNR) protein, and thus has significant anti-leukemia efficacy in vitro and in vivo. Monobenzone inhibits acute myeloid leukemia (AML) cells proliferation and DNA synthesis, induces cell cycle arrest, and Apoptosis .
    Monobenzone
  • HY-131906
    JAK2-IN-7

    		JAK FLT3 Apoptosis Cancer
    JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3 V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities .
    JAK2-IN-7
  • HY-101976
    JAK3-IN-6

    		JAK Inflammation/Immunology
    JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM.
    JAK3-IN-6
  • HY-169326S
    JAK2-IN-11

    		Isotope-Labeled Compounds JAK Cancer
    JAK2-IN-11 (Example 6) is a JAK2 kinase inhibitor with IC50 ≤10 nM against JH2 BIND WT/V617F. JAK2-IN-11 has antitumor activity .
    JAK2-IN-11
  • HY-13827
    JAK-IN-1
    4 Publications Verification

    		 JAK Inflammation/Immunology
    JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1.
    JAK-IN-1
  • HY-175684
    JAK2-IN-14

    		JAK STAT Apoptosis Cancer
    JAK2-IN-14 is an orally active JAK2 inhibitor with an IC50 of 2 nM. JAK2-IN-14 demonstrates 89.5-, 80.5-, and 51-fold selectivity over JAK1, JAK3, and TYK2, respectively. JAK2-IN-14 inhibits STAT5 signaling pathway. JAK2-IN-14 causes tumor cell cycle arrest and apoptosis. JAK2-IN-14 can used for the study of myeloproliferative neoplasms (MPNs) .
    JAK2-IN-14
  • HY-137756
    JAK2-IN-6
    1 Publications Verification

    		 JAK Cancer
    JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective JAK2 inhibitor with an IC50 of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells .
    JAK2-IN-6
  • HY-19544
    JAK3-IN-1

    		JAK Cancer
    JAK3-IN-1 is a potent, selective and orally active JAK3 inhibitor with an IC50 of 4.8 nM. JAK3-IN-1 shows over 180-fold more selective for JAK3 than JAK1 (IC50 of 896 nM) and JAK2 (IC50 of 1050 nM) .
    JAK3-IN-1
  • HY-151262
    JAK-IN-23
    1 Publications Verification

    		 JAK STING NF-κB STAT Inflammation/Immunology
    JAK-IN-23 is an orally active double inhibitor of JAK/STAT and NF-κB. JAK-IN-23 can inhibit JAK1/2/3 with IC50 values of 8.9 nM, 15 nM and 46.2 nM, respectively. JAK-IN-23 has potent inhibitory activities against interferon-stimulated genes (ISG) and NF-κB pathways with IC50 values of 3.3 nM and 150.7 nM, respectively. JAK-IN-23 has great anti-inflammatory that decreases the release of various proinflammatory factors. JAK-IN-23 can be used for the research of inflammatory bowel disease (IBD) .
    JAK-IN-23
  • HY-161684
    JAK2-IN-10

    		JAK STAT Cancer
    JAK2-IN-10 is a selective JAK2 V617F inhibitor with an IC50 value of ≤10 nM . JAK2-IN-10 can be used for the research of myeloproliferative neoplasms and other related diseases .
    JAK2-IN-10
  • HY-111471A
    JAK-IN-5 hydrochloride

    		JAK Inflammation/Immunology
    JAK-IN-5 hydrochloride is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283 .
    JAK-IN-5 hydrochloride
  • HY-153568
    JAK1-IN-11

    		JAK Cancer
    JAK1-IN-11 (compound 11) is a potent inhibitor of JAK，with IC50s of 0.02 nM (JAK1)，and 0.44 nM (JAK2)，respectively. JAK1-IN-11 has high selectivity against JAK1 over JAK2 .
    JAK1-IN-11
  • HY-116505
    JAK1-IN-4

    		JAK Cancer
    JAK1-IN-4 is a potent and selective JAK1 inhibitor, with IC50s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC50, 227 nM) .
    JAK1-IN-4
  • HY-161015
    JAK1-IN-13

    		JAK Inflammation/Immunology
    JAK1-IN-13 (compound 36b) is an orally active, potent and highly selective inhibitor of JAK1 with an IC50 of 0.044 nM. JAK1-IN-13 significantly decreases STAT3 phosphorylation .
    JAK1-IN-13
  • HY-126141
    JAK/HDAC-IN-1
    1 Publications Verification

    		 JAK HDAC Apoptosis Cancer
    JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC50s of 4 and 2 nM for JAK2 and HDAC, respectively .
    JAK/HDAC-IN-1
  • HY-174428
    PROTAC JAK2 degrader-1

    		PROTACs JAK STAT Apoptosis Cancer
    PROTAC JAK2 degrader-1 is a JAK2 PROTAC degrader, with a DC50 of 27.35 nM. PROTAC JAK2 degrader-1 induces JAK2 degradation via the ubiquitin-proteasome pathway. PROTAC JAK2 degrader-1 inhibits the JAK2-STAT signaling pathway. PROTAC JAK2 degrader-1 induces G2/M phase arrest and apoptosis in cancer cells. PROTAC JAK2 degrader-1 exhibits antiproliferative activity against cancer cells. PROTAC JAK2 degrader-1 inhibits recombinant human erythropoietin (rhEPO)-mediated polycythemia and splenomegaly in mice. PROTAC JAK2 degrader-1 can be used for research on myeloproliferative neoplasms, including polycythemia vera .
    PROTAC JAK2 degrader-1
  • HY-30272R
    Monobenzone (Standard)

    		DNA/RNA Synthesis Apoptosis Reference Standards Inflammation/Immunology
    Monobenzone (Standard) is the analytical standard of Monobenzone. This product is intended for research and analytical applications. Monobenzone is a potent skin depigmenting agent. Monobenzone induces depigmentation and active human vitiligo and exhibits good potential for vitiligo research .
    Monobenzone (Standard)
  • HY-143444
    JAK-IN-20

    		JAK Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    JAK-IN-20 is a potent, pan and orally active JAK inhibitor with an IC50s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo .
    JAK-IN-20
  • HY-100849
    JAK 3i

    		JAK Inflammation/Immunology
    JAK3i is a highly selective JAK3 inhibitor (IC50: 0.43 nM). JAK3i forms a covalent bond with a cysteine in JAK3, but not the closely related kinase domains in JAK1, JAK2, or TYK2. JAK3i abolishes IL-2-driven T-cell proliferation in vivo and has the potential for  autoimmune disease research .
    JAK 3i
  • HY-139423
    JAK1-IN-8

    		JAK Inflammation/Immunology Cancer
    JAK1-IN-8, a potent JAK1 inhibitor (IC50<500 nM), compound 28, extracted from patent WO2016119700A1 .
    JAK1-IN-8
  • HY-148060
    JAK-IN-21
    1 Publications Verification

    		 JAK Cancer
    JAK-IN-21 (Example 4) is a selective and potent JAK inhibitor with IC50s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively .
    JAK-IN-21
  • HY-155746
    JAK2-IN-9

    		JAK Infection Inflammation/Immunology
    JAK2-IN-9 (Compound A8) is a selective JAK2 inhibitor (IC50: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) .
    JAK2-IN-9
  • HY-179428
    JAK2-IN-17

    		JAK Cancer
    JAK2-IN-17 (compound 20) is a potent JAK2 allosteric inhibitor. JAK2-IN-17 inhibits full-length JAK2 and JAK2 V617F with IC50s of 160 and 130 nM, respectively. JAK2-IN-17 covalently modifies Lys677 in the pseudokinase domain .
    JAK2-IN-17
  • HY-144440
    JAK1-IN-9

    		JAK Cancer
    JAK1-IN-9 (compound 23a) is a potent and selective JAK1 inhibitor with an IC50 of 72 nM. JAK1-IN-9 shows selective against other JAKs by 12 times or more .
    JAK1-IN-9
  • HY-146727
    JAK3-IN-11

    		JAK Inflammation/Immunology
    JAK3-IN-11 (Compound 12), a potent, noncytotoxic, irreversible, orally active JAK3 inhibitor with IC50 value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3. JAK3-IN-11 strongly inhibits JAK3-dependent signaling and T cell proliferation, is a promising tool for study autoimmune diseases .
    JAK3-IN-11
  • HY-151285
    JAK-2/3-IN-3

    		Apoptosis JAK Inflammation/Immunology Cancer
    JAK-2-/3-IN-3 (compound ST4j) is a potent JAK2/3 inhibitor with IC50s of 13.00 and 14.86 nM for JAK2 and JAK3, respectively. JAK-2-/3-IN-3 inhibits autophosphorylation of JAK2 and induces apoptosis in a dose- and time-dependent manner. JAK-2-/3-IN-3 can be used in studies of lymph derived diseases and leukemia .
    JAK-2/3-IN-3
  • HY-18301
    JAK-IN-35

    		JAK Cancer
    JAK-IN-35 (compound XLVII) is a JAK2 inhibitor that canb be used in cancer research .
    JAK-IN-35
  • HY-117810
    JAK2-IN-1

    		JAK Inflammation/Immunology
    JAK2-IN-1 (eExample 2) is a JAK2 inhibitor, and can be used for research of proliferative disease, inflammatory disease, or renal disease .
    JAK2-IN-1
  • HY-145029
    SYK/JAK-IN-1

    		Syk JAK Cancer
    SYK/JAK-IN-1 is a dual Syk/Jak2 kinase inhibitor. SYK/JAK-IN-1 is applicable to cancer-related research .
    SYK/JAK-IN-1
  • HY-175983
    JAK1/TYK2-IN-5

    		JAK Cancer
    JAK1/TYK2-IN-5 (compound A1) is a JAK1/TYK2 inhibitor with Ki values of 0.0044 nM, 0.02 nM, 6.9 μM, 0.79 μM, 0.21 μM and 0.55 μM for TYK2 JH2, JAK1 JH2, JAK1 JH1, JAK2 JH1, JAK3 JH1 and TYK2 JH1, respectiverly. JAK1/TYK2-IN-5 inhibts IFNα induced TYK2/JAK1-mediated STAT activation .
    JAK1/TYK2-IN-5
  • HY-157121
    JAK-IN-34

    		JAK Inflammation/Immunology
    JAK-IN-34 (compound 11n) is a potent against of JAKs with IC50 values of 0.40, 0.83, 2.10, 1.95 nM target JAK1, JAK2, JAK3, TYK2, respectively. JAK-IN-34 reduces joint swelling with good safety .
    JAK-IN-34
  • HY-111471
    JAK-IN-5

    		JAK Inflammation/Immunology
    JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.
    JAK-IN-5
  • HY-14986
    JAK-IN-32

    		JAK Others
    JAK-IN-32 (XC) is a bi-aryl meta-pyrimidine inhibitor of JAK kinase .
    JAK-IN-32
  • HY-P5434
    Jak3tide

    jak3 Peptide substrate

    		 JAK Others
    Jak3tide (JAK3 Peptide substrate) is a biological active peptide. (This peptide is a substrate for Jak3. It may be used used in kinase assays. Jak3tide contains the phosphorylation site at Tyr7.)
    Jak3tide
  • HY-100759
    JAK2-IN-4

    		JAK Cancer
    JAK2-IN-4 (compound 16h) is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively .
    JAK2-IN-4
  • HY-178282
    JAK1-IN-19

    		JAK Inflammation/Immunology
    JAK1-IN-19 (Compound 18) is a potent JAK1 inhibitor with IC50s of 0.02, 0.5, 91 and 0.2 nM against JAK1, JAK2, JAK3 and TYK2. JAK1-IN-19 exhibits improved rat and human intrinsic clearance. JAK1-IN-19 can be used for the studies of atopic dermatitis and other autoimmune diseases .
    JAK1-IN-19
  • HY-174988
    JAK2-IN-13

    		JAK STAT Cancer
    JAK2-IN-13 is a potent and orally active JAK2 inhibitor with an IC50 of 54.7 nM. JAK2-IN-13 downregulates the expressions of p-STAT3 and p-STAT5. JAK2-IN-13 exhibits good bioavailability and potent inhibition of rhEPO-induced extramedullary erythropoiesis and polycythemia vera. JAK2-IN-13 can be used for the study of myeloproliferative neoplasms .
    JAK2-IN-13
  • HY-178936
    JAK2-IN-15

    		JAK STAT Inflammation/Immunology Cancer
    JAK2-IN-15 is an orally active, potent, selective JAK2 inhibitor (IC50 = 1.17 nM). JAK2-IN-15 can inhibit the AK2-STAT signaling pathway. JAK2-IN-15 significantly improves key pathological indicators such as hematocrit and splenomegaly in an Epoetin beta (HY-114134) (rhEPO)-induced mouse model. JAK2-IN-15 can be used for the study of Polycythemia Vera (PV) .
    JAK2-IN-15
  • HY-150688
    JAK3-IN-13

    		JNK Cancer
    JAK3-IN-13 (compound 12n) is a potent, selective and orally active JAK3 inhibitor with IC50 values of 4728, 2039, 8, 365 nM for NK1, JNK2, JNK3, Tyk2, respectively. JAK3-IN-13 shows antiproliferative activity. JAK3-IN-13 induces cell cycle arrest at G0/G1 phase. JAK3-IN-13 shows antitumor activity .
    JAK3-IN-13
  • HY-157011
    JAK-IN-33

    		JAK Inflammation/Immunology
    JAK-IN-33 (compound 3 (R)) is a JAK inhibitor .
    JAK-IN-33
  • HY-156535
    JAK kinase-IN-1

    		JAK Inflammation/Immunology
    JAK kinase-IN-1 (Example 1) is a JAK inhibitor. JAK kinase-IN-1 inhibits TYK2, JAK1, JAK2 and JAK3 with IC50 values of 4.2 nM, 32 nM, 27 nM, 3473 nM respectively .
    JAK kinase-IN-1
  • HY-128450
    JAK-STAT-IN-1

    		JAK STAT Inflammation/Immunology Cancer
    JAK-STAT-IN-1 (compound 1) is a selective JAK-STAT inhibitor. JAK-STAT-IN-1 can be used for the research of autoimmune disorder .
    JAK-STAT-IN-1
  • HY-149284
    JAK/HDAC-IN-3

    		JAK HDAC Cancer
    JAK/HDAC-IN-3 (13a) is a dual JAK and HDAC inhibitor, with IC50 values of 25.36 nM, 0.2 μM and 0.43 μM for JAK2, HDAC and HDAC1, respectively .
    JAK/HDAC-IN-3
  • HY-144058
    JAK-IN-18

    		JAK Inflammation/Immunology
    JAK-IN-18 is a potent inhibitor of JAK. JAK-IN-18 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2018204238A1, compound 1) .
    JAK-IN-18
  • HY-144057
    JAK-IN-17

    		JAK Inflammation/Immunology
    JAK-IN-17 is a potent inhibitor of JAK. JAK-IN-17 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2021185305A1, compound 9-1) .
    JAK-IN-17
  • HY-161621
    JAK-IN-37

    		JAK Inflammation/Immunology
    JAK-IN-37 (Compound WU4) is a JAK inhibitor, with IC50 values of 0.52, 2.26, 84 and 1.09 nM for JAK1, JAK2, JAK3 and JAK4, respectively. JAK-IN-37 can be used for the research of allogeneic hematopoietic cell transplantation (allo-HCT) .
    JAK-IN-37
  • HY-111750
    JAK-IN-3

    		JAK Inflammation/Immunology
    JAK-IN-3 (compound 22) is a potent JAK inhibitor, with IC50 values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively .
    JAK-IN-3
  • HY-139807
    JAK-IN-14

    		JAK Inflammation/Immunology
    JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC50 of <5 μM. JAK-IN-14 is >8-fold more selective for JAK1 than JAK2 and JAK3 (Patent WO2016119700A1, compound 16) .
    JAK-IN-14
  • HY-154994
    JAK-IN-30

    		JAK Inflammation/Immunology
    JAK-IN-30 (compound 31) is a water-soluble JAK inhibitor with IC50 values of 2, 15, 18 and 2 nM for JAK2, JAK1, JAK3 and TYK2, respectively. JAK-IN-30 has research potential for dry eye disease (DED) .
    JAK-IN-30
  • HY-147975
    JAK3-IN-12

    		JAK Inflammation/Immunology
    JAK3-IN-12 (compound 5k) is a highly potent JAK3 inhibitor with IC50 values of 9.5 nM, 18 nM and 42 nM for JAK3, JAK1 and JAK2, respectively. JAK3-IN-12 can be used for researching rheumatoid arthritis .
    JAK3-IN-12

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: